<DOC>
	<DOCNO>NCT01952990</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics safety nasal spray contain anesthetic drug Tetracaine combination Oxymetazoline healthy pediatric subject .</brief_summary>
	<brief_title>Safety Pharmacokinetics Kovacaine Nasal Spray Pediatric Subjects</brief_title>
	<detailed_description>The purpose study determine pharmacokinetics safety tetracaine , para- butylaminobenzoic acid ( PBBA ) , oxymetazoline intranasal administration recommend , weight-based Phase 3 dose Kovacaine Mist ( Tetracaine Hydrochloride Oxymetazoline Hydrochloride ) healthy pediatric subject . Kovacaine Mist anesthetic solution contain 3 % tetracaine hydrochloride 0.05 % oxymetazoline hydrochloride . A single spray dose 100 μL Kovacaine Mist contain 3 mg tetracaine HCl 0.05 mg oxymetazoline HCl . A two-100 μL spray dose ( total 200 μL ) Kovacaine Mist contain 6 mg tetracaine HCl 0.1 mg oxymetazoline HCl . A two-200 μL spray dose ( total 400 μL ) Kovacaine Mist contain 12 mg tetracaine HCl 0.2 mg oxymetazoline HCl . Kovacaine Mist administer base weight subject summarize table . Subjects weigh 10 &lt; 20 kg receive 1 intranasal spray 100 μL Kovacaine Mist time D0 . Subjects weigh 20 &lt; 40 kg receive 2 intranasal spray 100 μL ( total dose 200 μL ) administer 4 minute apart time D0 D4 . Subjects weigh 40 kg receive 2 intranasal spray 200 μL ( total dose 400 μL ) administer 4 minute apart time D0 D4 .</detailed_description>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Tetracaine</mesh_term>
	<criteria>Male female 317 year age inclusive . Sufficiently healthy determine investigator receive test medication . Accompanied and/or represent parent guardian able comprehend sign inform consent document . Subject able understand provide assent ageappropriate subject assent form ( defined local practice regulation ) . Patient parent/guardian able communicate investigator comply requirement protocol . Within 10th 90th percentile weight age . Can breathe nostril . Body mass index 14 30 kg/m2 inclusive . Any chronic currently uncontrolled psychiatric , neurological , endocrine , pulmonary , cardiovascular , renal , gastrointestinal hepatic disease condition manifestation might confound interpretation study result make receipt study medication source risk adverse outcome . Inadequately control thyroid disease type . Has clinically significant abnormal finding physical examination , medical history , clinical laboratory evaluation screening . Currently experience seasonal perennial allergic rhinitis , recurrent nosebleed asthma , significant history condition , opinion Investigator . Current , include last 30 day , sinusitis upper respiratory infection , nasal congestion use `` sinus medication '' within 48 hour prior anticipate study participation . Nasal polyp , significant nasal sinus surgery abnormality may interfere dose administration . History allergy intolerance tetracaine , oxymetazoline , benzyl alcohol , ester local anesthetic , paraaminobenzoic acid ( find PABAcontaining sunscreen ) . Use monoamine oxidase inhibitor within 3 week precede study entry . Nursing , pregnant , suspected pregnant , try become pregnant . ( Females childbearing potential require undergo urine test baseline visit rule pregnancy . ) Having receive investigational drug ( include Kovacaine Mist ) and/or participation clinical trial within 30 day study participation . History congenital idiopathic methemoglobinemia . Anticipated need use oxymetazoline phenylephrine nasal spray , nasal irrigation , nasal oral decongestant day study procedure . Have history pseudocholinesterase deficiency previous prolonged paralysis succinylcholine difficulty wake general anesthesia . Fever define body temperature ≥100.4 ( 38°C ) day prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Pharmacokinetic</keyword>
</DOC>